Claritev Corporation (CTEV) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with revenue and EBITDA growth, improved margins, and significant pipeline expansion. Despite some uncertainties in the regulatory environment, the positive Q4 guidance and successful client renewals suggest continued stability and growth. The Q&A section provided clarity on future revenue conversion and highlighted operational improvements. Overall, the company is well-positioned for growth, leading to a positive stock price outlook over the next two weeks.
Key Financial Performance
Revenue Total revenue in Q3 was $246 million, up 6.7% year-over-year. The increase was attributed to strong performance in core offerings, including network revenue growth of nearly 15%, analytics growth of 4.2%, and payment revenue integrity growth of over 7%. Additionally, a new commercial arrangement in the P&C business contributed approximately $5 million of nonrecurring revenue benefit.
Adjusted EBITDA Adjusted EBITDA was $155.1 million for the quarter, reflecting a 9.5% growth rate year-over-year. This growth was driven by strong performance in core offerings and disciplined cost management.
EBITDA Margins EBITDA margins were 63.1% in Q3 and 62.8% year-to-date, tracking to full-year guidance. The improvement was due to strong revenue growth and cost discipline.
Core Revenue Core revenue grew approximately 3% year-to-date, supported by strength in Data iSight and Financial Negotiations solutions, which showed strong savings and revenue per claim performance despite slightly lower volumes.
Annual Contract Value (ACV) Closed $15 million in ACV in Q3, bringing the year-to-date total to $45 million. The average ACV per transaction increased by more than 25% year-over-year, driven by pipeline growth and expansion in existing and new client opportunities.
Pipeline Growth The pipeline grew by 67% year-to-date, with an additional net $80 million in new pipeline during the first 9 months of 2025. This growth was attributed to diversification efforts and the expansion of the go-to-market team.
Unlevered Free Cash Flow Unlevered free cash flow was $113 million in Q3, the strongest in 9 quarters. This was driven by lower cash paid for income taxes net of refunds and strong operational performance.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Advanced Code Editing (ACE): Posted strong double-digit growth and poised for broader deployment to new end markets.
BenInsights and PlanOptix: Integrated with QinetiQ for health and wellness consulting services.
Analytics and CompleteVue: Driving revenue up, costs down, and improving efficiency for healthcare providers.
International Expansion: Launched advanced code editing solution in UAE and signed partnerships with iO Health and Klaim in the MENA region.
Broker and Employer Market: Signed over 100 deals, including a premier broker agreement, and hosted a Broker Virtual National Summit with 300 attendees.
Provider Market: Signed EPHC, a 13-hospital consortium, to use payment accuracy and market analytics solutions.
Revenue Growth: Achieved 6.7% revenue growth and 9.5% adjusted EBITDA growth in Q3, marking the best revenue performance in 12 quarters.
Client Renewals: Renewed top 10 clients for extended terms, providing stability and visibility.
Pipeline Growth: Achieved a 67% increase in pipeline year-to-date, with $45 million in ACV closed year-to-date.
Focus on Core Solutions: Aligned to six focused market verticals with accountable leaders and sales incentives.
Digital Transformation: Migrated to Oracle Cloud Infrastructure (OCI) and modernized applications for better speed and data integration.
Healthcare Market Alignment: Aligned with government initiatives on price transparency and reducing waste, with active engagement in discussions.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and reimbursement pressures: The healthcare industry faces structural, regulatory, and reimbursement pressures, which could impact Claritev's operations and financial performance.
Healthcare inflation: Healthcare inflation is anticipated to rise 6% to 9%, which could increase costs and create challenges for Claritev's clients and operations.
Fragmentation in healthcare: Fragmentation in the healthcare industry drives inefficiency and waste, posing challenges for Claritev to address these systemic issues effectively.
Rising employer plan costs and shifting employee burdens: Rising costs for employer plans and shifting financial burdens to employees could impact demand for Claritev's solutions and client satisfaction.
Complex regulation: The complexity of healthcare regulations, including NSA and surprise billing compliance, could create operational challenges for Claritev.
Economic uncertainties in international markets: Expansion into international markets, such as the Middle East, introduces economic uncertainties and potential risks related to adapting solutions to new regions.
Dependence on top clients: Renewal of top 10 clients provides stability, but heavy reliance on these clients could pose risks if any major client relationship deteriorates.
Supply chain and operational risks: Investments in technology and transformation programs could face delays or inefficiencies, impacting Claritev's ability to deliver on its strategic goals.
Behavioral health high-cost cases: An increase in high-cost cases, particularly in behavioral health, could strain resources and impact financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Claritev raised its full-year revenue guidance to approximately 2.8% to 3.2% growth versus the prior year, supported by strong Q3 performance and a robust pipeline.
Adjusted EBITDA Margin: The company tightened its adjusted EBITDA margin guidance range to 62.5% to 63%, reflecting operational efficiency and strong financial performance.
Capital Expenditures: Claritev narrowed its forecasted CapEx spend range to $165 million to $175 million, focusing on investments in innovation and operational excellence.
Market Trends: Healthcare inflation is anticipated to rise 6% to 9%, with stable out-of-network claims at 5% to 7% and an increase in high-cost cases, particularly in behavioral health. Claritev's analytics and platforms are positioned to help clients optimize benefit plans and control costs.
Growth Pipeline: The company expects to book approximately $60 million of incremental Annual Contract Value (ACV) in 2025, which will largely convert to revenue in 2026 and beyond. The pipeline has grown by 67% year-to-date, with opportunities across all business lines.
International Expansion: Claritev launched its advanced code editing solution in the UAE ahead of schedule and signed partnerships with iO Health and Klaim to accelerate AI-driven solutions. The international market is seen as a significant growth opportunity.
Strategic Partnerships: The company is actively working on embedding solutions within Oracle's human capital management products and expanding its payments business through partnerships like Klaim, which focuses on healthcare payment acceleration.
Government Vertical: Claritev is engaging in discussions aligned with government initiatives on price transparency and waste reduction, with expectations of near-term positive developments.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you explain the guidance for Q4, particularly regarding revenue and EBITDA margin?
A:Doug Garis explained that the Q4 guidance implies a quarter up roughly 2% to 6% on revenue with EBITDA up roughly 3% to 9%. He mentioned that the company is running ahead of internal expectations and may opportunistically pull forward capital projects or OpEx to drive revenue growth.
Q:What are the expected headwinds or tailwinds for 2026, and is mid-single-digit revenue growth reasonable?
A:Doug Garis stated that mid-single-digit revenue growth in the second half of 2026 is reasonable. He highlighted tailwinds such as healthcare inflation, sequential improvements in PSAV volumes, and higher-dollar out-of-network inpatient claims. However, he noted uncertainties like the regulatory environment and government shutdowns.
Q:Are the 10 client renewals headwinds or tailwinds, and were they renewed at similar terms?
A:Doug Garis and Travis Dalton confirmed that the 10 client renewals are not headwinds but rather tailwinds, providing stability and opportunities for growth. The renewals were conducted at stable levels, and the company views them as foundational for achieving stability and growth.
Q:How should we interpret the $60 million of new ACV signed this year?
A:Doug Garis explained that the $60 million of new ACV is incremental to the core business and will largely convert to revenue next year. He estimated that 60% to 65% of the ACV will convert to revenue in 2024, with some deals taking a few quarters to show up as revenue.
Q:What is the update on NSA products and the market trend?
A:Doug Garis and Travis Dalton noted that the NSA business is performing well despite structural challenges, such as providers winning 80% of disputes. They highlighted operational improvements, including a 70% reduction in unit costs for servicing IDR claims, and emphasized continued investment in NSA products and automation.
Q:How does Claritev get paid on NSA disputes, and where is this revenue reported?
A:Doug Garis explained that Claritev captures a percentage of the savings on the negotiated rate or win rate for NSA disputes. The revenue is reported under analytics-based services, specifically within the PSAV business.
Q:What additional context can you provide about the client renewal process?
A:Travis Dalton emphasized that client renewals were a major focus, with efforts to ensure clients understood the value of current and new capabilities. He highlighted the renewal of a single client as a significant achievement, providing predictability and stability for the business.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance for 2026, citing uncertainties in the pricing and inflationary environment. They also used vague language when discussing the regulatory environment and government shutdowns, without offering concrete details or timelines.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACE digit
ACV date
ACV transaction
ACV volume
AI Advanced
AI World
AI healthcare
Annual
ECHO
EPHC
HR
Health
Klaim
MENA region
analytics solution
arrangement
aspiration
color
consumer
core Claritev
core solution
date basis
detail minute
dollar
end market
expansion market
flow cash
focus discipline
funnel
highlight
hospital
market opportunity
market vertical
number opportunity
people
principle
quarter
shout
solution core
stability visibility
trend
value solution
CTEV Transcript
Claritev Corporation (CTEV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Claritev Corporation (CTEV) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call highlights a solid financial performance with 8% revenue growth and improved operating margins. The increase in net income and free cash flow further supports a positive outlook. Despite the lack of discussion on strategic initiatives or shareholder returns, the financial metrics suggest a positive market reaction. The absence of significant concerns in the Q&A reinforces this sentiment. Given the company's focus on AI-driven solutions and international expansion, the stock price is likely to see a positive movement in the short term.
Claritev Corporation (CTEV) Q4 2025 Earnings Call Prepared Remarks Transcript
Positive2-24
The earnings call highlights strong financial performance with a 10% revenue increase and improved operating margins. Strategic initiatives in AI and international expansion, alongside a robust dividend and share buyback program, support positive sentiment. Despite risks and reliance on non-GAAP measures, the optimistic revenue and margin projections, coupled with shareholder returns, suggest a positive outlook.
Claritev Corporation (CTEV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-15
CTEV Slides
CTEV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
